Last reviewed · How we verify
rivaroxaban and ticagrel therapy
Rivaroxaban and ticagrelor together provide dual anticoagulation and antiplatelet therapy to prevent thrombotic events.
Rivaroxaban and ticagrelor together provide dual anticoagulation and antiplatelet therapy to prevent thrombotic events. Used for Acute coronary syndrome with high thrombotic risk, Prevention of thrombotic events in patients requiring dual antithrombotic therapy.
At a glance
| Generic name | rivaroxaban and ticagrel therapy |
|---|---|
| Sponsor | Beijing Anzhen Hospital |
| Drug class | Anticoagulant and antiplatelet combination therapy |
| Target | Factor Xa (rivaroxaban); P2Y12 receptor (ticagrelor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Rivaroxaban is a Factor Xa inhibitor that blocks the coagulation cascade, while ticagrelor is a P2Y12 platelet receptor antagonist that inhibits platelet aggregation. Combined, they provide complementary antithrombotic effects through different pathways—one targeting the coagulation cascade and the other targeting platelet function—to reduce clot formation in high-risk cardiovascular conditions.
Approved indications
- Acute coronary syndrome with high thrombotic risk
- Prevention of thrombotic events in patients requiring dual antithrombotic therapy
Common side effects
- Bleeding
- Dyspnea
- Bradycardia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rivaroxaban and ticagrel therapy CI brief — competitive landscape report
- rivaroxaban and ticagrel therapy updates RSS · CI watch RSS
- Beijing Anzhen Hospital portfolio CI